CHESTER, N.J., Feb. 15 /PRNewswire/ -- Adams Respiratory Therapeutics ("Adams") announced today a business transaction involving the AlleRx(TM) & Humibid(TM) families of products. Effective today, Adams will transfer the AlleRx(TM) family of prescription respiratory medications to Cornerstone BioPharma, which will in turn transfer the Humibid(TM) trademark to Adams. Humibid(TM) is currently marketed as an OTC product under the names Humibid(TM) e and Humibid(TM) CS.
The Humibid(TM) trademark will complement Mucinex(R), the company's flagship brand of OTC respiratory medications.
"The Humibid(TM) brand is highly regarded among the professional healthcare community and was prescribed approximately 2 million times during calendar year 2004," said Michael J. Valentino, President and CEO of Adams. Valentino continued, "We intend to leverage the brand equity and prescription heritage that Humibid(TM) enjoys in the professional community as we add to our portfolio of products."
About Adams Respiratory Therapeutics
Based in Chester, New Jersey, Adams Respiratory Therapeutics develops, markets and sells prescription and non-prescription pharmaceuticals for the treatment of respiratory disorders and diseases. More information can be found on the company's Web site at http://www.adamsrt.com/.
Adams Respiratory Therapeutics
CONTACT: Kajal Jhaveri of Ruder Finn, +1-212-593-5864,email@example.com, for Adams Respiratory Therapeutics